Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Patient characteristics by DU severity*

From: Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden

Patient characteristics by number of DUMild DU*Moderate DU*Severe DU*p value
 n (%) or mean ± SD
Median (IQR 25th–75th)
n (%) or mean ± SD
Median (IQR 25th–75th)
n (%) or mean ± SD
Median (IQR 25th–75th)
 
Patient number308 (74.8%)60 (14.6%)44 (10·7%) 
Demographics
 Age at SSc onset, years43.9 ± 14.542.8 ± 12.143.4 ± 12.30.56
 Female gender286 (84.9%)54 (83.1%)29 (65.9%)0.01
 Limited disease subtype230 (68.5%)30 (46.2%)12 (27.3%)< 0.001
 Alive239 (79.9%)51 (85.0%)28 (68.3%)0.12
 Smoke (past or current)169 (50.2%)33 (50.7%)28 (63.6%)0.24
DU severity (highest no of DU)
 Mild (1–5 digital ulcers on exam)337 (75.6%)65 (14.6%)44 (9.9%) 
 Moderate (6–10 digital ulcers on exam)   N/A
 Severe (> 10 digital ulcers on exam)    
Autoantibody profile**
 Anti-centromere pattern ANA (n = 437)159 (48.2%)17 (26.6%)5 (11.6%)< 0.001
 Scl 70 + ve (n = 432)53 (16.3%)19 (30.2%)21 (48.8%)< 0.001
 RNA polymerase III + ve (n = 300)35 (15.4%)17 (36.9%)4 (15.4%)0.03
Clinical manifestations***
 Telangiectasia ever321 (95.3%)64 (98.5%)44 (100%)0.18
 Calcinosis ever188 (55.8%)42 (64.6%)29 (65.9%)0.53
 Joint contractures194 (57.6%)55 (84.6%)39 (88.6%)< 0.001
 GIT involvement305 (90.5%)62 (95.4%)39 (88.6%)0.38
 SSc Renal Crisis12 (3.6%)1 (1.5%)3 (6.8%)0.35
 PAH#59 (17.5%)6 (9.2%)5 (11.4%)0.17
 ILD104 (30.9%)25 (38.5%)27 (61.4%)< 0.001
Hospitalized in the last 12 months for
 Digital ulcers71 (23.1%)22 (36.7%)17 (38.6%)0.04
 Intravenous antibiotics therapy34 (11.0%)13 (21.7%)11 (25.0%)0.02
 Intravenous prostanoids60 (19.5%)18 (30.0%)16 (36.4%)0.04
 Surgical debridement22 (7.1%)6 (10.0%)5 (11.4%)0.18
Medications
 CCB258 (76.6%)54 (83.1%)38 (86.4%)0.21
 PDE5 inhibitor64 (18.9%)17 (26.2%)13 (29.5%)0.05
 ERAs72 (21.4%)9 (13.8%)8 (18.8%)0.36
 Iloprost92 (27.3%)22 (38.9%)21 (47.7%)0.02
 Topical vasodilators44 (13.1%)10 (15.4%)9 (20.5%)0.39
HRQoL
 Physical component score (PCS)36.6 ± 10.635.3 ± 9.631.3 ± 9.80.02
 Mental component score (MCS)46.5 ± 13.343.4 ± 12.645.9 ± 12.40.38
  1. Abbreviations: DU digital ulceration, PAH pulmonary arterial hypertension, ILD interstitial lung disease, GIT gastrointestinal tract, CVA cerebrovascular accident, PVD peripheral vascular disease, ACA anticentromere, Scl-70 antitopoisomerase-1, RNAP anti-RNA Polymerase III, CCB calcium channel blockers, ERAs endothelial receptor antagonists, PDE5 phosphodiesterase-5 inhibitors, SSc scleroderma
  2. Health-related quality of life (HRQoL) was defined using the SF-36 study short form which provides a score range from 0 to 100.·Scores below 50 indicate worse HRQoL than the population normative score and every 10 points indicates 1 standard deviation.·These scores can be summarized into the physical component score (PCS) and mental component score (MCS), scores below 50 indicate worse HRQoL than the population normative score and every 10 points indicates 1 standard deviation
  3. *DU severity was calculated based on the physician reported highest number of new DUs on examination at clinical review (mild 1–5 new DU, moderate 6–10, and severe > 10 new DU)